The invention relates to a compound of formula (I)

##STR00001##

wherein R.sup.1 to R.sup.3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

The invention relates to a compound of formula (I)

##STR00001##

wherein R.sup.1 to R.sup.3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.

Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.

The invention provides compounds having the general Formula (I);

##STR00001##

and pharmaceutically acceptable salts thereof; wherein the variables R.sup.A, R.sup.AA, subscript n, subscript q, ring A, X.sup.2, L, subscript m, X.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compounds having the general Formula (I);

##STR00001##

and pharmaceutically acceptable salts thereof; wherein the variables R.sup.A, R.sup.AA, subscript n, subscript q, ring A, X.sup.2, L, subscript m, X.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Crystals of (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N,2-dimethylmalonamide having diffraction peaks at diffraction angles (2) of 3.80.2, 7.70.2, and 10.80.2, etc., or 8.20.2, 12.40.2, and 13.30.2, etc., in powder X-ray diffraction, a production method thereof, and a pharmaceutical composition.

Crystals of (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzoyl)(methyl)amino)-N-hydroxy-N,2-dimethylmalonamide having diffraction peaks at diffraction angles (2) of 3.80.2, 7.70.2, and 10.80.2, etc., or 8.20.2, 12.40.2, and 13.30.2, etc., in powder X-ray diffraction, a production method thereof, and a pharmaceutical composition.

The present disclosure is directed to resins and to polymers, copolymers, and blends formed therefrom.

The present disclosure is directed to resins and to polymers, copolymers, and blends formed therefrom.